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1. Introduction
Chronic obstructive pulmonary diseasese (COPD) is the fourth leading cause of mortality and
its prevalence continues to increase. While the debilitating effects of COPD on daytime
functioning are well known, COPD’s effects on sleep have been less fully investigated. Sleep
problems affect as many as 50% of patients with COPD. The mild hypoventilation that is
physiologically observed during sleep is heightened in this patient group and is often accom‐
panied by ventilation/perfusion mismatch. Significant hypoxemia ensues that is often accom‐
panied by hypercapnia. These gas exchange abnormalities (particularly nocturnal oxygen
desaturation, NOD) place COPD patients at increased risk of pulmonary hypertension,
arrhythmias, and possibly cardiovascular death. Approximately 50% of COPD patients with
mild daytime hypoxaemia experience NOD which suggests that NOD may be a frequent
occurrence with devastating consequences in individuals with COPD.
The increased prevalence of obesity worldwide is associated with a subsequent increase in the
occurrence of sleep disordered breathing, particularly obstructive sleep apnea (OSA). The co-
existence of OSA and COPD, known as the overlap syndrome, has been estimated to occur in
1% of the general population. The presence of one of the disorders, however, potentiates the
occurrence of the other by more than 10%. Overlap patients are a unique group of COPD
patients who experience complex sleep disordered breathing, with nocturnal hypoxaemia and
hypercapnia that is often disproportionately worse than their ventilatory impairments,
pulmonary hypertension, and significant cardiovascular comorbidity. Evidence of systemic
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inflammation and oxidative stress in both COPD and OSA provides a common pathophysio‐
logic link between these disorders which may predispose these individuals to increased
cardiovascular morbidity and mortality. Further studies of the overlap syndrome are required
to provide information on the additive and/or synergistic effects of these disorders at the
molecular, physiological, and clinical level. Current, ongoing, long-term studies will provide
information on the clinical consequences of the overlap syndrome, especially regarding
cardiovascular mortality.
Despite the lack of understanding of the pathophysiologic processes mediating the develop‐
ment and effects of the overlap syndrome, treatment with continuous positive airway pressure
(CPAP) reduces hypoxaemia, pulmonary and systemic hypertension, and improves survival.
Furthermore, CPAP reduces exacerbations and lung decline in patients with the overlap
syndrome.
Thus, a more aggressive approach in diagnosing OSA in COPD patients is strongly recom‐
mended. This chapter will acquaint you with the physiology of breathing in normal subjects
and those with COPD, OSA, and overlap syndrome. We will review the effects of these
disorders on sleep quality, gas exchange, and cardiovascular comorbidity. The current
diagnostic and treatment options will be introduced. The role of oxidative stress in cardiovas‐
cular and metabolic comorbidity in OSA and overlap will also be discussed from our research
perspective. The effect of bilevel positive pressure ventilation for one month on sleep quality,
gas exchange, and ventilatory parameters, insulin resistance, and oxidative stress in overlap
syndrome will also be reviewed.
2. Sleep and ventilation
2.1. Sleep and ventilation in normal physiology
Based upon the electroencephalographic characteristics, sleep can be divided into non-rapid
eye movement sleep (NREM) and rapid eye movement sleep (REM) which have unique
physiological characteristics. The four stages of NREM sleep are categorized by the presence
of sleep spindles, K-complexes, and distinctive electro-occulogram and electromyogram
findings. REM sleep is characterized by bursts of rapid eye movement, muscle atonia, and
shallow and irregular breathing. It is subdivided into two periods: tonic and phasic. Four to
five cycles of recurring NREM and REM episodes occur throughout the night. The duration
of REM sleep increases during the night, being longest in the last part of nocturnal sleep. Sleep
profoundly affects breathing by altering respiratory drive, minute ventilation, and ventilation/
perfusion matching.
2.1.1. Respiratory drive
The physiological mechanisms of breathing during sleep are similar to those in wakefulness
except for the fact that feedback mechanisms are blunted. This dampening effect is mostly
attributed to the slight decrease in the metabolic rate during sleep which attenuates the
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response to mechanical, cortical, and metabolic stimuli [1,2]. The ventilatory and arousal
responses to hypercapnia are much more robust than for hypoxia, with only slight changes in
PaCO2 causing recognizable alterations of minute ventilation [3]. However, under normal
conditions in sleep and especially during periods of REM, the responses to hypoxaemia and
hypercapnia are blunted in comparison to wakefulness. The diminished ventilatory responses
to hypercapnia and hypoxia are more profound during REM compared with NREM sleep [1,
4]. These attenuated feedback mechanisms stress the respiratory system which in individuals
with COPD is already deranged and dysfunctional. The combinations of sleep disordered
breathing, impaired respiratory function, and dampened feedback interactions may cause
significant reductions in minute ventilation and precipitate respiratory failure
2.1.2. Minute ventilation
Compared to wakefulness, minute ventilation decreases during NREM sleep and declines even
further during REM sleep when minute ventilation may be 15% less than occurs during
wakefulness. The minute ventilation decrease is caused by a reduction in tidal volume due to
muscle atonia and cephaloid displacement of the diaphragm that is not fully compensated by
an increase in respiratory frequency [5]. The consequence is sleep related hypoventilation
which causes a significant reduction (2-8 mmHg) in the partial pressure of oxygen in arterial
blood (PaO2) and an increase in the partial pressure of carbon dioxide (3-10mmHg) in arterial
blood (PaCO2) [6]. The decreased muscle tone during sleep increases respiratory resistance
and the inability to compensate for these changes probably contributes to attenuated physio‐
logic responses [7]. During NREM sleep, the phasic electromyographic activity of the genio‐
glossus and geniohyoid muscles is well-maintained [8], but tonic activity of upper airway
dilator muscles decreases [9]. During REM sleep, breathing is shallow and irregular and upper
airway resistance increases due to full skeletal-muscle atonia [10].
2.1.3. Ventilation-perfusion mismatch
During NREM sleep, lung volume decreases leading to a reduction in the functional residual
capacity (FRC) [11]. Reduction in lung compliance and reduced respiratory muscle tone, have
been suggested as potential causal factors in the reduction in FRC [12]. It has been hypothesized
that reduced FRC during sleep may contribute to the airway closure, causing ventilation–
perfusion mismatch and, thus, contributing to the small changes in arterial oxygen saturation
especially during REM sleep [13].
2.2. Sleep and ventilation in COPD patients
The control of breathing in patients with COPD follows the same basic principles as in normal
subjects. The lower baseline oxygenation and abnormal respiratory mechanics in patients with
COPD become clinically important when combined with the normal physiologic alterations
in ventilatory control and respiratory muscle tone that occur during sleep. In COPD patients,
the more profound decrease in oxygen saturation during sleep is mainly attributed to the lower
PaO2 during wakefulness. This PaO2 level is on a steeper section of the O2 dissociation curve;
thus, a slight decline in oxygenation leads to a more profound reduction in oxygen saturation.
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Thus, nocturnal oxygen desaturation (NOD) is the most significant sleep abnormality associ‐
ated with COPD [14,15]. Even without any upper-airway contribution, various studies have
reported that 27–70% of patients with COPD with awake oxygen saturation levels of 90 –95%
can experience substantial desaturation at night, particularly during REM sleep [16-18].
2.2.1. Definition of NOD
The definition of NOD varies depending on various studies. At least three different definitions
have been used: 1) Mean nocturnal oxygen saturation (SaO2) < 90%; 2.) SaO2 < 90% for more
than 30% of recording time (total time in bed); 3) SaO2 < 90% for more than 5 minutes of
recording time with a nadir <=85%. Most studies use either definition 2 or 3 [19]. Similarly, the
definition for the amount of desaturation dip is not universal. Wynee and colleagues [20]
defined a desaturation dip by a fall in SaO2 by more than 4% from baseline during quiet
breathing just before the episode of hypoxemia. Flenley’s group [6,21] defined a dip as a 10%
or greater drop in SaO2.
The nocturnal oxygen desaturation in COPD patients presents specific characteristics. It takes
place at the end of the night during REM sleep [22] and may be variable from one night to the
other, especially in patients with moderate-to-severe COPD [23]. The desaturations are
significantly related to daytime hypoxaemia and hypercapnia [24]-the more pronounced
daytime hypoxaemia and hypercapnia, the more severe nocturnal desaturation [25].
2.2.2. Mechanisms of NOD
Flenley [25] identified three mechanisms that might contribute to nocturnal oxygen desatura‐
tion: 1) alveolar hypoventilation; 2) decreased ventilation/perfusion matching; 3) decreased
end-expiratory lung volume. Subsequent research confirmed much of his hypothesis. The
description of sleep disordered breathing, particularly, obstructive sleep apnea, led to the
introduction of the overlap syndrome in 1985 as an independent phenomenon in COPD
patients [25].
2.2.2.1. Alveolar Hypoventilation
Alveolar hypoventilation plays a significant role in NOD, especially during REM sleep. The
exact mechanism causing alveolar hypoventilation in COPD patients is arguable. This may be
due to the type of measurements performed, the stage of sleep (REM vs. NREM), and the status
of subjects-normocapnic or hypercapnic COPD patients. Becker et al [5] observed a drop in
minute ventilation of 16% and 32% during non-REM and REM sleep, respectively. This
reduction was predominantly due to a decrease in tidal volume measured by a pneumota‐
chograph. The greater drop in minute ventilation in subjects with COPD may reflect increased
dependence on accessory muscles that become hypotonic during sleep, particularly during
REM sleep, as well as the presence of blunted chemical respiratory drive. Ballard and cow‐
orkers [10] showed a decrease in minute ventilation in COPD patients which was associated
with an increase in upper airway resistance as well as a decrease in neuromuscular output to
the respiratory muscles rather than a decrease in lung volumes. O’Donoghue et al [26] noted
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a decline in minute ventilation in NREM sleep in hypercapnic COPD patients due to a decrease
in tidal volume and an increase in upper airway resistance. Although the exact mechanism is
unknown, current evidence suggests that alveolar hypoventilation during sleep contributes to
NOD in COPD patients.
2.2.2.2. Ventilation-perfusion (V/Q) mismatch
V/Q mismatch has not been directly measured during sleep. However, for a mild and similar
increase in PaCO2 (and thereby alveolar hypoventilation), some COPD patients had more
significant decreases in nocturnal PaO2 than others, suggesting a role for V/Q mismatch as a
mechanism for NOD [24]. This may be due to reduced lung volumes (particularly functional
residual capacity-FRC) caused by declines in respiratory muscle tone leading to atelectasis at
the lung bases. It is likely that in COPD patients, especially during REM, the ventilation/
perfusion mismatch may be due to the dissociation between intercostal and diaphragmatic
activity on one hand [22] and the cephaloid displacement of the diaphragm and decreased
FRC on the other [27].
2.2.2.3. Impact of oxyhemoglobin dissociation curve
Hypoxaemic patients at baseline are more likely to drop their SaO2 with hypoventilation
during sleep, compared to normoxic patients due to the effect of the oxyhemoglobin dissoci‐
ation curve [22]. Mild decreases in oxygenation change the location on the oxygen-hemoglobin
dissociation curve from the plateau to the edge of the slope where a slight decrease in oxy‐
genation will cause a profound decline in oxygen saturation. This effect is not an independent
mechanism but contributes to the NOD in collaboration with other factors.
2.2.2.4. Obstructive sleep apnea (Overlap syndrome)
Patients with coexisting obstructive sleep apnea (overlap syndrome) may be hypoxaemic at
the commencement of an apnea and thus are more likely to desaturate compared to patients
with only OSA who may be able to recover to a normal SaO2 after the apneic episode. Overlap
syndrome and its mechanisms and consequences will be discussed in detail.
2.2.3. Consequences of NOD
Potential consequences of NOD are mainly related to cardiovascular mortality and morbidity
and affect pulmonary haemodynamics mainly.
2.2.3.1. Pulmonary hypertension
Alveolar hypoxemia is the major mechanism that triggers pulmonary arterial vasoconstriction
and leads to pulmonary hypertension [28]. In a study of 12 patients with COPD, an acute
increase in pulmonary artery pressure was noted in all sleep stages, most significantly in REM.
The increase corresponded much more to the decrease in PaO2 compared to the rise in
PaCO2 [29]. Although highly persuasive, there is still not enough evidence for a causational
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link between sleep oxygen desaturation episodes and the development of pulmonary hyper‐
tension in COPD patients.
Pulmonary haemodynamic studies during sleep in COPD patients have been scarce as the
invasive nature of their investigation is not compatible with normal sleep [30]. Moreover
almost all of them are in severe COPD patients with daytime hypoxaemia, marked nocturnal
hypoxaemia, and daytime pulmonary hypertension (pulmonary artery pressure (PAP) > 20
mm Hg) [31-33]. Nocturnal elevation of PAP appears to correlate with NOD in this patient
population [33]. Whether this correlation stays true in patients with mild and moderate COPD
with less diurnal hypoxaemia is elusive.
In patients with mild and moderate COPD, studies on the relationship between pulmonary
hypertension and NOD are not conclusive and their interpretation depends on the type of
definition used for NOD, as well as the amount of decrease in PaO2 [34,35,36]. Fletcher et al [34]
studied 36 COPD patients who had daytime PaO2 > 60 mm Hg and NOD during REM sleep
(a drop in SaO2 < 90% for 5 minutes or more and a nadir of at least 85%). They measured an
increase in systolic and mean pulmonary artery pressures, as well as pulmonary vascular
resistance. In forty COPD patients with a daytime PaO2 of 60-70 mm Hg, Levi-Valensi et al [35]
detected higher mean pulmonary artery pressures in those individuals with NOD compared
with those who did not have NOD (defined as SaO2 < 90% for > 30% of total time in bed (TIB)).
In a larger group of 66 COPD patients with a daytime PaO2 >60 mm Hg, Chaouat et al [16]
found no difference in the mean pulmonary artery pressure measured by right heart cathe‐
terization. NOD was defined by the same criteria used by Levi-Valensi.
In conclusion, acute nocturnal oxygen desaturation is associated with increases in both
systemic and pulmonary blood pressures [34]. It is very likely that the repetitive, transient
nocturnal oxygen desaturations that appear in some COPD patients can cause pulmonary
hypertension [37]. Which patients are more likely to be affected by NOD and what clinical
factors predict the hemodynamic effects of NOD are unknown. It is, however, generally
assumed that patients with COPD and daytime normoxia who have only nocturnal oxygen
desaturation generally do not develop substantial pulmonary hypertension. This assumption
is supported by the lack of efficacy of nocturnal supplemental oxygen in treatment trials in
this patient population [38]
2.2.3.2. Cardiac arrhythmias
Various arrhythmias are reported during episodes of nocturnal desaturation [4]. These
consequences might explain why nocturnal oxygen desaturation is a marker of increased
mortality and why COPD patients are reported to die more frequently at night than expected
[39]. Though some studies have shown increased frequency of premature supraventricular
and ventricular contractions (PVC) during sleep in COPD patients, overall there appears to be
no correlation between PVC’s and nocturnal SaO2 [40,41].
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2.2.3.4. Polycythemia
Daytime hypoxaemia in COPD patients is a well known cause of polycythemia. However,
NOD without daytime hypoxaemia has not been associated with polycythemia [35,42]. In
addition, there is no clear evidence that erythropoetin is increased in COPD patients with
primary NOD [43].
2.2.3.5. Sleep quality
NOD can also affect sleep quality. Arousals may be related to episodes of desaturation [44]
and, consistent with this observation, some (but not all) studies have shown that supplemental
oxygen improves sleep quality [6].
2.2.3.6. Mortality
While some COPD patients die due to respiratory failure, they more frequently die from
cardiovascular disease or malignancy [45]. There is some evidence that these deaths occur
predominantly at night. McNicholas reported that patients admitted to the hospital with
chronic bronchitis or emphysema were more likely to die at night than other hospital patients.
Deaths occurred more frequently among so called “blue-bloaters” [39]. Although these data
relate to patients with daytime hypoxaemia, the effect of NOD on survival of COPD patients
without significant daytime hypoxemia is not well established. Fletcher et al [34] performed a
retrospective study in 169 COPD patients without daytime hypoxemia. NOD was define‐
deither as a drop in SaO2 below 90% for 5 or more minutes reaching a nadir of 85% or as
SaO2 <90% for > 30% of TIB. Although patients with NOD had improved survival compared
to the non-NOD group, correcting NOD has not shown to improve survival. In 97 COPD
patients, Connaughton et al [46] found no survival advantage when they followed them for a
median of 70 months, performing nocturnal SaO2 measurement.
Comorbid OSA was recently reported to increase mortality in patients with COPD. Marin et
al, published outcome data on patients with COPD and patients with the overlap syndrome,
both with and without CPAP treatment [47]. Subjects were initially screened because of a
clinical suspicion of sleep-disordered breathing. Then, a diagnostic polysomnogram and
spirometry were performed. After a median follow-up of over 9 years, all-cause mortality was
higher in the untreated (without CPAP) overlap group (42.2%) than in the COPD-only group
(24.2%). Even after adjustment for COPD severity, comorbid OSA remained a risk factor for
death. In this study, death in the untreated overlap group was most commonly attributed to
cardiovascular disease. In the overlap group, OSA contributed to an increased incidence of
COPD exacerbations, which may accelerate lung-function decline and, hence, augment
mortality [48,49]
The exact mechanism(s) for the increased mortality risk in overlap syndrome is not established.
Increased risk of death may be due to more prolonged hypoxia. Nighttime hypercapnia may
also be important. The systemic consequences of both COPD and OSA should also be consid‐
ered. They both cause inflammation and oxidative stress. Whether these mechanisms are
additive or synergistic is, however, unknown.
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3. Sleep quality in copd
3.1. Characteristics of sleep disturbances
Insomnia and other sleep problems are increased in patients with COPD [44]. Elderly COPD
patients experience more morning tiredness and early awakenings [50]. The most commonly
reported sleep disturbances are insomnia, poor sleep maintenance, early morning awakenings
and headaches, and daytime sleepiness. These symptoms occur in approximately 30-70% of
patients with COPD [44, 50, 52]. When surveyed for a broad range of symptoms, “sleep
difficulties” were mentioned as occurring “almost always” or “always” in 43% of subjects with
either chronic bronchitis or emphysema and were the third (after dyspnea and fatigue) most
common complaint [53]. The sleep architecture of individuals with COPD is notable for many
arousals. These arousals were attributed not just to the diagnosis of COPD, but largely due to
the presence of related symptoms-cough, sputum production, or wheezing. These symptoms
correlated most with difficulty falling or staying asleep [53]. Many COPD patients report use
of hypnotics (28% compared to controls-10%) to combat sleep disturbances [44].
Subjective complaints of sleep disturbances appear to be associated with the presence of
objective evidence for disturbed sleep quality in patients with COPD (predominantly in small
cohorts of patients with severe COPD) as documented by overnight polysomnograms (PSGs).
These findings include increased sleep latency, decreased total sleep time, decreased sleep
efficiency, increased nocturnal arousals, decreased slow-wave sleep, and decreased REM sleep
[6,20,44,54]. Cormick et al found significant agreement between subjective complaints of
initiating and maintaining sleep and objective findings of poor sleep quality as shown by a
decreased total sleep time of 208 minutes and increased arousal index [44].
Sleep disturbances may not be as pervasive in patients with mild/moderate COPD. The Sleep
Heart Health Study (SHHS) did not show altered sleep quality in mild COPD patients (FEV1/
FVC 63.81±6.56%) [55]. Sanders et al observed that COPD only patients had minimally
perturbed sleep and found no correlation between the decline in FEV1 and sleep architecture.
In a community-based study, Redline et al [56] showed that sleep structure variables did not
change in subjects with a history of lung disease. In addition, they found that sleep stage
distributions varied in accordance with AHI level.
3.1.1. Mechanisms of sleep disturbances in COPD patients
Various reasons for sleep disturbances in COPD patients exist. The most common are cough,
dyspnea, nocturnal oxygen desaturation (NOD), hypercapnia, degree of airway obstruction
(measured by FEV1), and medication side effects [6,20,44,54,57]. Although SHHS suggests a
lesser degree of effect on sleep quality in patients with milder COPD, no clear relationship
between sleep quality measures and FEV1 is established [50]. Poor-quality of sleep may be
associated with hypoxaemia and increased superficial sleep [58].
COPD Clinical Perspectives124
3.1.2. Consequences of sleep disturbances
The poor sleep quality in COPD patients may lead to decreased daytime functioning due to
excessive daytime sleepiness, altered neurocognition, and psychomotor vigilance. There are
no studies that address whether neurocognition or psychomotor vigilance are affected in
COPD patients. COPD patients often complain of daytime sleepiness. However Orr et al [59]
found no objective evidence for daytime sleepiness based on multiple sleep latency testing in
14 severe COPD patients who had poor sleep quality based upon decreased total sleep time
and increased arousal index.
4. Predictors of nod in copd patients
Approximately 27–70% of patients with COPD with awake SaO2, 90–95%, can experience
substantial desaturation at night, especially during REM sleep [20,24]. The high prevalence of
NOD and its consequences on haemodynamics are a challenge for many researchers who have
attempted to determine daytime physiological parameters that might help in predicting NOD
in COPD. Although NOD is more pronounced in COPD patients with daytime hypoxaemia,
it is established that an additional quarter of patients with adequate oxygenation during
wakefulness can experience NOD [20,24].
4.1. Severe COPD
In severe COPD, the ‘blue bloater’ rather than the ‘pink puffer’ phenotype is more likely to
have NOD [60]. Various studies showed that the blue bloaters had lower baseline oxygen
saturations, more episodes of NOD, larger falls in NOD, and spent more time at low levels of
oxygen saturation while asleep, than the pink puffers [6,20,21]. A significant relationship
between waking values of low PaO2 and high PaCO2 with NOD was also established [42,44,61].
Moreover, although there was a good correlation between mean sleep SaO2 and mean exercise
SaO2, the awake PaO2 appeared to be a better predictor for NOD than exercise desaturation
[24]. The desaturation nadir was lower during sleep than during exercise, with oxygen
saturation falling an average of 6 ± 4% during peak exercise and 13 ± 9% during sleep [62].
Pulmonary function testing correlated poorly with nocturnal hypoxaemia[55].
In summary, most evidence suggests that awake oxygen saturation is a better predictor for
NOD in severe COPD patients than PFT parameters or exercise desaturations [24,63]. Increased
daytime PaCO2 also carries an increased risk for NOD [55].
4.2. Mild and moderate COPD
The clinical approach to NOD detection in COPD is more difficult in patients with mild/
moderate COPD (GOLD I-II) and mild daytime hypoxaemia. Approximately one quarter of
these individuals have NOD, which is independent of the co-existence of OSA [42]. Current
guidelines for evaluation of nocturnal oxyhemoglobin saturation in COPD patients without
significant daytime hypoxaemia, however, are restrictive. Measuring nocturnal oxyhemoglo‐
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bin saturation in COPD patients who have daytime PaO2-55–59 mm Hg is not recommended
[64]. Polysomnography should be performed in COPD patients whose symptoms are sugges‐
tive of coexistent OSA.. Other high risk groups include is COPD patients with daytime
hypercapnia and only moderately reduced FEV1; obese snorers, those who develop headache
after nocturnal oxygen therapy, and patients with mild hypoxaemia and unexplained poly‐
cythemia, pulmonary hypertension, and cor pulmonale [64]. Witnessed apneas while asleep
and daytime sleepiness are also highly suspective of OSA [65]. However, the presence of
concomitant OSA is often difficult to predict from daytime symptoms in patients with mild/
moderate COPD. They do not have daytime hypercapnia, headache, or daytime sleepiness.
Classic sleep complaints and daytime sleepiness are not common. COPD alone, when mod‐
erate, does not disturb sleep quality, and OSA may not always present with sleep complaints.
So if sleep complaints are the trigger for polysomnography in mild/moderate COPD, a large
number of patients will not be tested.
5. Diagnostic approaches to detecting nod in copd patients
Nocturnal oximetry alone is probably not helpful diagnostically in COPD patients, as noctur‐
nal oxygen desaturation may reflect only COPD or some combination of COPD and OSA, and
treatment will differ (see below). Definitions of nocturnal oxygen desaturation differ, and
physician decision and management based on nocturnal oximetry results differ greatly.
Finally, there is little evidence that correction of nocturnal hypoxemia in COPD with only
nocturnal desaturation improves outcomes [38].
Epidemiological data suggest that nocturnal oxyhemoglobin desaturation either related or
unrelated to OSA is present in at least 50% of COPD patients without significant daytime
hypoxaemia. Considering that approximately half of these patient have coexistent OSA,
clinicians should establish the diagnosis of OSA in these patients. Nocturnal oxymetry should
be performed in severe COPD, in mild and moderate COPD patients with the clinical charac‐
teristics listed in table 1. Patients with COPD who are diagnosed with nocturnal hypoxaemia
by nocturnal oxymetry should undergo attended nocturnal polysomnography to exclude
coexistent OSA.
Mild COPD Severe COPD
Daytime hypoxemia disproportionate to FEV1 Blue boaters
Daytime Hypercapnia disproportionate to FEV1 Daytime hypoxemia PaO2 < 55 mmHg





Table 1. Indications for performing a nocturnal oxymetry in mild/severe COPD
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6. Osa as a mechanism for nod
Obstructive sleep apnea (OSA) is an independent phenomenon, leading to sleep-disordered
breathing that is characterized by a cessation (apnea) or limitation (hypopnea) of airflow
accompanied by a desaturation (Figure 1). OSA is diagnosed when more than 5 apneas and
hypopneas occur per hour of sleep and are associated with excessive daytime sleepiness. OSA
and COPD are two common respiratory diseases whose combination was first noted by Flenley
[25] and is now recognized as the classic overlap syndrome (Figure 2). Both OSA and COPD
have systemic inflammatory consequences that are responsible for increased cardiovascular
morbidity and mortality. Moreover, until recently, OSA itself was categorized as an inflam‐
matory consequence of COPD [66]. For this, as well as many other reasons, OSA and the
overlap syndrome will be discussed separately in this chapter. Although they share common
manifestations, COPD and OSA are united in the overlap syndrome, presenting a unique
combination of upper and lower airway resistance and a blunted respiratory drive. In overlap
patients, these disorders have more than an additive or synergistic effect, but rather present
as an independent sleep-related breathing abnormality.
Figure 1. Polysomnogram of a patient with OSA only (note the desaturations highlighted by the circles and arrows)
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Figure 2. Polysomnogram of a patient with overlap syndrome (the desaturation is more severe; desaturations are
highlighted by the circles and arrows)
6.1. Sleep and respiration in OSA
During apneas, the collapsed pharynx impedes airflow in spite of the respiratory effort. The
obstruction leads to progressive asphyxia, which additionally stimulates breathing against the
collapsed airway and usually continues until the person awakens [67]. Various factors-upper
airway anatomy, central respiratory control mechanisms etc., contribute to the development
of the clinical syndrome of OSA. The primary defect might be an anatomically small or
collapsible pharyngeal airway, in combination with sleep-induced upper airway muscle atonia
[68,69]. Instability of ventilatory control [70,71] or inefficiency of the central respiratory drive
that modulates upper airway resistance in OSA may be other factors responsible for this
disorder [72]. Abnormal hypoxic and hypercapnic respiratory response has also been reported
in hypercapnic OSA patients [73,74]. The role of reduced chemical feedback is, however, still
under debate. It is not clear whether the abnormal hypoxic and/or hypercapnic respiratory
response is secondary to sleep apnea or is an inherited abnormality in ventilatory control [75,
76]. The improvement in the ventilatory feedback to CO2 in hypercapnic OSA patients after
CPAP therapy suggests that this dysregulation is acquired and not genetic [77,78].
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6.2. OSA and COPD – predisposing factors and prevalence
Whether any pathophysiological link exists between OSA and COPD is still unknown, but
they share common risk factors and pathophysiological processes that contribute to the genesis
and exacerbation of each other. The relationship between COPD and OSA may be influenced
by smoking and BMI. Neck obesity contributes to upper airway narrowing while truncal
obesity promotes ventilatory disturbances by reduced chest wall compliance and muscle
strength. Visceral obesity is responsible for reduced residual capacity and contributes to
ventilation/perfusion mismatch. BMI may be lower in some patients with COPD, especially
those with advanced disease and may be protective against OSA [27,65].
Smoking is another risk factor for COPD that, in addition, predisposes to sleep apnea. It
increases airway resistance due to local inflammation and edema. Besides BMI and smoking,
OSA and COPD may by themselves contribute to the onset of each other.
Redolfi et al [79] demonstrated that, even in healthy subjects, there is an overnight fluid shift
from the legs that increases neck circumference. In COPD patients with cor pulmonale and
peripheral edema, rostral fluid shifts that occur during supine positioning may contribute to
pharyngeal narrowing and favour the onset of obstructive apneas/hypopneas. The corticoste‐
roid induced myopathy or the cachexia that occurs in advanced COPD stages may be the
reason for blunted inspiratory force. Local pharyngeal muscle edema associated with steroid
inhalations might contribute to upper airways narrowing, thus facilitating sleep/disordered
breathing [80]. Increased end-expiratory lung volume within an individual improves upper-
airway mechanics, probably via tracheal traction. In emphysematous COPD patients, although
end-expiratory lung volume may be elevated, the loss of lung recoil may not be protective for
upper-airway mechanics. It is assumed that the decreased tethering of airways by destruction
of parenchyma may actually produce a more collapsible upper airway [81]. Repetitive upper-
airway collapse increases lower-airway resistance in an animal model suggesting that OSA
might itself promote COPD [82]. Finally, in order to lose or maintain weight, or to fight
excessive daytime sleepiness, patients with OSA might smoke more frequently than those
without it [83].
6.3. Epidemiology
Initial studies may have overestimated the prevalence of overlap syndrome [84]. Patients with
obstructive lung disease, referred mostly for evaluation of excessive daytime sleepiness, were
determined to frequently have OSA as well [85]. In early studies, a high prevalence of OSAS
was found in individuals with COPD. Guilleminault et al [86] studied 26 COPD patients while
sleeping and found that 92% of all abnormal respiratory events during sleep contained an
obstructive component. Conversely, patients with known OSA were evaluated with spirome‐
try and 11% were found to have an FEV1/FVC < 0.60 l [87]. Another study found the prevalence
of the overlap syndrome to be 29%, although the data were gathered in a retrospective chart
study of patients who had been refered for polysomnography and who also had an interpret‐
able pulmonary function test [88]. The seemingly very high prevalence prompted speculation
that OSA and COPD were linked by a common mechanism or common pathophysiology.
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Recently, however, data from the Sleep Heart Health Study, a prospective multicenter cohort
study showed that overlap syndrome has a prevalence of 14% among patients with mild COPD
which is not different from those without COPD (18.6%) [55]. The presence of airway obstruc‐
tion did not seem to affect the respiratory disturbance index. The Multinational Monitoring of
Trends and Determinants in Cardiovascular Disease [MONICA-II]) also found no increased
risk between the two disorders [89]. The major limitation of these studies, however, is that
most subjects had very mild airway obstruction on spirometry.
Although there may be no increased association between relatively mild COPD and OSA
because of the rising prevalence of these diseases, a patient with one of the disorders will often
have the other disease. For example, in the Sleep Heart Health Study and the MONICA-II
study, GOLD stage II COPD was found in 19% and 11% of the subjects with OSA, respectively.
Sleep-disordered breathing was seen in 14% of subjects in the Sleep Heart Health Study
(respiratory disturbance index > 15 events/h) and 11% of subjects (AHI > 5 events/h and
excessive daytime sleepiness) in the MONICA-II cohort [55,89]. A patient with one of the
disorders has a greater than 10% chance of also having the other. Thus, when seeing a patient
with either OSA or COPD, it is reasonable to screen for the other disorder.
Our experience generally confirms the findings from the SHHS and MONICA II cohorts. From
January–December, 2011, we performed a prospective study of patients with complaints of
daytime sleepiness, witnessed apneas and/or hyponeas who were referred to the Sleep Lab,
Division of Pulmonology, Clinic of Internal Medicine, University Hospital Alexandrovska,
Sofia. Only patients who signed informed consent participated in the study. The aim of the
study was to compare the anthropometric, metabolic, cardiovascular, and respiratory charac‐
teristics of patients with OSA and overlap syndrome. Gas exchange and ventilatory parameters
were also compared. The level of oxidative stress, measured by the urinary concentration of
8-isoprostanes was of special interest. A correlation between oxidative stress and cardiovas‐
cular and metabolic comorbidity was investigated. Patients were followed for a month after
the initiation of bilevel positive pressure ventilation (BiPAP). The effect of this treatment
modality on the level of oxidative stress, gas exchange, and ventilatory parameters measured
by pulmonary function testing was studied.
Patients who agreed to participate in the study underwent a full polysomnography (Compu‐
medics, Australia). Continuous recordings were taken with electrode positions C3/A2-C4/A1-
Cz/01 of the international 10–20 Electrode Placement System; eye movements, chin
electromyogram, and ECG modified V2 lead were also recorded. Sleep was scored manually
according to standard criteria. Airflow was measured using nasal pressure associated with the
sum of buccal and nasal thermistor signals. Respiratory efforts were monitored with abdomi‐
nal and thoracic bands. Arterial oxygen saturation (SpO2) was measured using a pulse
oximeter. An apnoea was defined as a complete cessation of airflow for >10 s, and a hypopnoea
as a > 50% reduction in the nasal pressure signal or a 30–50% decrease associated with either
oxygen desaturation of >3% or an arousal (defined according to the Chicago report or by
autonomic activations on pulse transit time), lasting for at least 10 s. Apnoeas were classified
as obstructive, central, or mixed according to the presence or absence of respiratory efforts.
The diagnosis of OSA was established if the AHI was > 5 events/h [90].
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For the period of the study, 265 patients with newly diagnosed OSA signed an informed
consent to participate in the study. COPD was determined in accordance with the GOLD
criteria, 2011 – FEV1/FVC <70% after administration of a bronchodilator [91]. 26 (9.8%) patients
(23 men; 3 women) were diagnosed with overlap syndrome. All patients had stage II COPD
(80%> FEV1<50%). These findings corroborate the results of larger epidemiological studies
measuring the prevalence of overlap syndrome in patients with moderate COPD.
6.4. Overlap syndrome and physiological consequences
6.4.1. Gas exchange
The majority of patients with OSAS are eucapnic during wakefulness. Daytime hypercapnia
is usually associated with mechanical impairment of the respiratory system related to obesity
and/or COPD [92,93]. It is also associated with the severity of OSA, higher BMI levels, or degree
of restrictive chest wall mechanics. Hypoxaemia is also described in OSA. It is closely related
to apneas and hypopneas and is a result of alveolar hypoventilation.
In overlap syndrome, however, there is a predisposition to daytime hypercapnia and hypo‐
xaemia that is independent of lung function [16]. Nocturnal desaturation severity varies within
the wide spectrum of sleep-disordered breathing and the severity of COPD. In overlap
patients, the nocturnal desaturation is greater and lasts longer than in patients with either
OSAS or COPD. OSA seems to be an important cause of hypercapnia and hypoxemia in some
COPD patients that is disproportionate to their lung function impairment. Chan et al [94]
showed that hypercapnic COPD patients have higher BMI and smaller airway cross sectional
areas when compared with lung function matched eucapnic controls. Furthermore, it is known
that overlap patients have more nocturnal desaturation events than patients with either COPD
or OSA alone [55]. Sanders and colleagues examined the degree to which COPD and OSAS
independently and jointly contribute to desaturations during sleep [55]. After adjusting for
confounding factors, the odds ratio for nocturnal oxyhemoglobin desaturation (SpO2 < 85%
for more than 20% of total sleep time) was 20 times greater in OSA and 30 times greater in
overlap syndrome. Bednarek et al [89] demonstrated that patients with overlap syndrome had
lower mean arterial blood oxygen saturations and spent more time in desaturation than the
OSAS group when polysomnography variables were compared.
These observations are confirmed by our own investigations. We compared overlap syndrome
patients to patients with OSA alone. Patients with OSA had a moderate degree of sleep
disordered breathing with an average AHI – 24.11± 5.34 events/h. They were compared to AHI
and age matched patients with overlap syndrome. The overlap patients had an average AHI
– 28.14±5.47 events/h. 21(80%) patients had moderate OSA (AHI 15-30 events/h); 5 (20%) had
mild OSA (AHI 5-15 events/h). The average desaturation in overlap and OSA was 12.3% vs
6.9% (p=0.037), respectively. The proportion of sleep time with SaO2<90% in the overlap group
was greater, 57.21%, in comparison with the OSA only group, 34.8 %, p=0.042.
The nighttime respiratory disturbances reflected the daytime gas exchange parameters. In
overlap patients, the average daytime PaO22 was 61.67±5.78 mmHg vs 75.59±8.43mmHg in
OSA. The prevalence of hypercapnic patients was greater in the overlap (19.2%) with an
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average daytime PaCO2 in the group – 52.14±11.39 mmHg. In the OSA only group, hypercapnia
was detected in 1 patient (4%) and the average PaCO2 was 36.25±6.11 mmHg. Thus, our
investigation shows that patients with overlap syndrome experience longer and more severe
nighttime desaturations that disturb gas exchange parameters in comparison to OSA patients
with similar AHI
The mechanisms responsible for the gas exchange abnormalities in overlap syndrome are
complex. Radwan et al [95] compared the breathing pattern and CO2 response in 11 obese male
overlap syndrome patients, 20 obese male OSAS patients with normal lung function, and 13
healthy nonobese controls. Overlap patients with hypercapnia had both blunted ventilatory
and mouth occlusion pressure responses to CO2 and their ventilatory response may also be
disturbed. The repetitive inspiratory effort against an occluded airway and intermittent
hypoxia may be deleterious for the inspiratory muscles in severe OSA. In overlap syndrome
patients, this increased fatiguability is even more accentuated, which is related to the mechan‐
ical disadvantage of chest wall hyperinflation and reduced functional residual capacity [96].
Moreover, it is established that overlap syndrome patients hypoventilate not only during the
night but also during the day. The reason is still unknown. When measured, their chemosen‐
sitivity is reduced compared to those with OSA alone. It is elusive whether this is a cause or
an effect of the overlap syndrome [95]. It is interesting to speculate that overlap syndrome
patients have a genetic predisposition to hypercapnia, or that the higher PaCO2 reflects the
increased muscle load in those with both increased upper and lower airway resistance.
Inflammation, nocturnal PaCO2 elevations, and/or obesity (for example, leptin has been
implicated as a modulator of respiratory drive) may be the triggers changing the PaCO2 set-
point [97].
In summary, the pathophysiology of sleep disordered breathing is complex in overlap
syndrome and mainly associated with upper and lower airway obstruction and a reduction in
respiratory drive. Hyperinflation may cause fatigue of respiratory muscles. Moreover, the
functional residual capacity is reduced because of the supine posture and sleep state which
predisposes the patient to ventilation/perfusion mismatch.
6.4.2. Pulmonary haemodynamics and right heart failure
OSAS patients may have sustained pulmonary hypertension (PH) [98,99,100] and the risk for
its development increases further in the presence of COPD, obesity or both [101,102]. Chaouat
et al [87] observed that the prevalence of PH was 42% in overlap syndrome compared with
OSA alone (13%). They found that the main determinants of pulmonary hypertension in
overlap syndrome were daytime arterial blood gases and FEV1. Moreover, overlap patients
often have relatively mild abnormalities (spirometry or oxygenation), especially when
compared to COPD-only patients with pulmonary hypertension. Overlap patients with
pulmonary hypertension have an average FEV1 of 1.8 L, FEV1/FVC of 0.64, and awake PaO2 of
64 mm Hg. COPD-only patients with pulmonary hypertension have more severe obstructive
disease, with FEV1 < 1 L, FEV1/FVC <0.50, and awake PaO2 < 55 mmHg. Fletcher [17] demon‐
strated that in overlap syndrome, FEV1/FVC was 60%. Patients with COPD and daytime
normoxia who have only nocturnal oxygen desaturation generally do not develop substantial
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pulmonary hypertension [38]. PH is usually observed in COPD patients with daytime
PaO2<55±5 mmHg. According to Chaouat et al [87], PH develops in patients with overlap
syndrome at even higher daytime PaO2 levels (PaO2>66±10mmHg) than in patients with
COPD.The mean PaO2 in sleep is certainly lower due to the synergistic effect that both
disorders have on pulmonary haemodynamics and gas exchange. Hawrylkiewicz and
colleagues observed that 16% of OSA patients had pulmonary hypertension compared with
86% of those with overlap syndrome [103]. In regression analysis, traditional markers of OSA
severity, such as the AHI or oxygen saturation nadir, have generally not correlated with the
presence of pulmonary hypertension. Even patients with severe OSA alone do not tend to
develop marked pulmonary hypertension if they are free from other cardiopulmonary diseases
[102]. The degree of pulmonary hypertension if any, is mild and of uncertain clinical impor‐
tance [37,103,104].
In our overlap group, pulmonary hypertension was detected in 84.6% of patients who had an
average systolic pulmonary pressure of 38.87 mmHg. In the group of patients with OSA,
pulmonary hypertension was found in only 47.8% with an average systolic pulmonary
pressure of 34.16 mmHg. Both the time spent at SaO2<90% (57.2% vs. 34.8%) and the average
desaturation index (12.3% vs 6.9%) were greater in the overlap vs OSA group. In overlap
patients, the average daytime PaO2 was 61.67±5.78 mmHg vs 75.59±8.43 mmHg in those with
OSA; the average daytime PaCO2 was 52.14±11.39 mmHg vs 36.25±6.11 mmHg in the OSA
only group.
The ventilatory parameters in overlap patients were disproportionate to the level of gas
exchange parameters and poorer than in the OSA only group. Comparing those with overlap
syndrome to those with OSA, forced vital capacity (FVC) was 55.5±24.5% vs 77.25± 19.6%;
forced expiratory volume in 1 s (FEV1) was 53.5±10.87% vs 62.25±20.22; FEV1/FVC was
64.46±9.19% vs 86.9±8.85%, respectively.
According to our results, the degree of PH was of similar range in both patient groups. The
prevalence of pulmonary hypertension in the overlap syndrome was almost two fold greater
than in the OSA only group. It is, however, disproportionate to what should be expected from
the gas exchange and ventilatory parameters. Before making final conclusions, we should point
out that our study was performed in patients with extreme obesity and that pulmonary
hypertension was determined by echocardiography which may not be the most accurate
measure of pulmonary pressures. The cardiovascular comorbidity, smoking status as well as
the higher BMI in overlap syndrome prevented the precise analysis of the clinical factors
associated with PAP in overlap and OSA patients.
In summary, in overlap patients, nocturnal desaturation is greater, lasts longer, and is
associated with more pronounced daytime hypoxemia and hypercapnia. The combination of
OSA and COPD may be associated with increased pulmonary and systemic blood pressures
as well as greater cardiovascular morbidity.




Mortality in patients with the overlap syndrome has not been well studied until recently.
COPD patients frequently die from cardiovascular disease predominantly at night. It can be
speculated that some of these patients may have had the overlap syndrome. Similarly, OSA
patients have also been shown to die disproportionately at night, compared to control groups,
who are at greatest risk during the morning hours [105]. Tachyarhythmias are very likely to
be responsible for nighttime deaths in both patient groups. In COPD patients, ventricular
premature contractions occur commonlyin sleep when the SaO2 is < 80%. In OSA patients, the
entire spectrum of cardiac arrhythmias may be observed. Olmetti et al [106] showed that in
COPD patients with concomitant OSA, tachyarrhythmias are more common.
The diagnosis of concomitant COPD and reduced FEV1 or smoking history are markers for
increased mortality in OSA patients [107-109]. In a univariate analysis, COPD conferred a 7-
fold risk of death in OSA patients [108]. Vice versa, comorbid OSA was recently reported to
increase mortality in patients with COPD. Marin et al [47] presented outcome data on patients
with COPD and patients with the overlap syndrome. After a median follow-up of over 9 years,
all-cause mortality was higher in the untreated (no CPAP) overlap group (42.2%) than in the
COPD-only group (24.2%). After adjustment for COPD severity, comorbid OSA remained a
risk factor for death. An intriguing issue in that study is that OSA may also contribute to an
increased incidence of COPD exacerbations, which may accelerate lung-function decline and
lead to increased mortality [48,49].
Mermigkis et al demonstrated that, in addition to the increased morbidity and mortality,
patients with the overlap syndrome also have significantly worse quality of life (measured
with the St George’s Respiratory Questionnaire), when compared to COPD-only controls [110].
The overlap syndrome patients in their study were COPD patients with habitual snoring but
without excessive daytime sleepiness or elevated Epworth sleepiness score which underscores
how difficult clinical diagnosis and screening of snoring in non-sleepy COPD patients may be.
6.5. Inflammation, oxidative stress and cardiovascular and metabolic comorbidity in overlap
The exact mechanisms that account for the increased morbidity and mortality risk in overlap
syndrome are not known exactly. Increased risk of death may be due to prolonged hypoxia.
Nighttime hypercapnia may also be important. There is enough evidence that both COPD and
OSA have systemic consequences since both cause inflammation and oxidative stress.
6.5.1. Inflammation and oxidative stress
Systemic inflammation is being recognized as a risk factor for a number of complications
including atherosclerosis [111]. It is a well-established factor in the pathogenesis of cardiovas‐
cular disease (CVD) [112]. There is growing recognition that COPD is a systemic disease
[113,114] with multiple effects on end-organs including those in the cardiovascular system
[115,116].
Patients with OSA experience persistent low grade inflammation, mainly attributed to
repetitive episodes of hypoxia/ reoxygenation during apneas and hypopneas while asleep.
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This inflammation is associated with increased arterial stiffness, blood pressure [117,118] and
increased risk for hypertension, heart failure, stroke, and cardiovascular mortality. The
molecular pathways of systemic inflammation in OSA and COPD may be similar, suggesting
a multiplicative effect in overlap syndrome.
CRP is an acute phase protein that contributes to atherosclerosis. Its plasma levels are elevated
in OSA, but obesity is the major confounder because there is no evidence for an independent
relationship between OSA and CRP [119,120]. IL-6, another inflammatory marker, is increased
in OSA even after adjustment for BMI [121]. Further, IL-6 and CRP are elevated in stable COPD
patients and increase during exacerbations [122,123].
NF-kB is a regulator of inflammatory gene expression and controls the synthesis of cytokines
(TNF-α, IL-8) [112] that increase expression of adhesion molecules and contribute to athero‐
sclerosis [124]. Hypoxia is the major trigger for the activation of both adaptive and maladaptive
transcription factors. Ryan et al [125] showed that sustained hypoxia is responsible for the
expression of adaptive hypoxia inducible factor (HIF)-a molecule promoting the expression of
genes which stimulate tissue perfusion and oxygenation. Intermittent hypoxia (apnea/
hypopnea events in OSA, NOD in REM induced hypoventilation of COPD patients and
overlap patients) is a trigger for NF-kB activation [112]. Thus, we hypothesize that, in OSAS
as well as in COPD with overlap, there may be synergistic activation of “overlapping”
pathways leading to inflammation. This hypothesis explains the evidence of increased
inflammation observed in both COPD and OSA. TNF-α and IL-8 are elevated in COPD and
OSA when compared to control subjects [126]. Both molecules are well established risk factors
for coronary artery disease and heart failure [127].
Furthermore, oxidative stress occurs in COPD and OSAS and is associated with increased ROS
[128,129] which are produced by intrapulmonary leukocytes in COPD and circulating
leukocytes in OSA [128,130]. Although ROS are important physiologic regulators in many
signaling pathways, their increased production may cause abnormal oxidation of DNA,
proteins and lipids and may contribute to vascular endothelial dysfunction [131].
In our investigation, we tried to compare the degree of oxidative stress, measured by the
urinary concentration of 8-isoprostanes. The study was performed in 26 overlap patients and
23 age and AHI matched OSA patients. None of them had been treated with CPAP or oxygen.
An overnight urine sample was collected and the levels of urinary 8-isoprostane were
determined by HRAM (high resolution accurate mass) mass spectrometry on a LTQ Orbi‐
trap® Discovery (ThetmoScientific Co, USA) mass spectrometer equipped with a Surveyor®
Plus HPLC system and IonMax® electrospray ionization module. The analyses were performed
using the stable isotope dilution method in negative ionization mode with a HESI II (heated
electrospray ionization) source type. The concentration and purification of 8-isoprostane from
urine samples was processed by affinity sorbent (Cayman Chemical, USA), according to the
manufacturer’s protocol. The urinary isoprostane levels were standardized to the levels of
urinary creatinine which were measured using the enzyme method (Creatinine plus version
2 (CREP2), Cobas Integra (Roche)). In overlap patients, the average values were higher than
in OSA patients, 0.251±0.10 pg/mkmol/cre vs. 0.185±0.06 pg/mkmol/cre, p<0.05. The urinary
isoprostane levels did not correlate with the respiratory disturbance parameters (AHI, average
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desaturation, time of sleep at SaO2<90%), gas exchange parameters (PaO2/PaCO2) or with the
ventilatory parameters (FVC, FEV1, FEV1/FVC).
We confirmed that in overlap patients the degree of oxidative stress is higher irrespective of
the parameters mentioned above. The exact mechanisms of oxidative stress as well as its
consequences were not determined in our study.
Abnormally activated leucocytes in COPD and OSA may also be a mechanism for atheroscle‐
rosis [112]. A systemic metaanalysis has shown that circulating neutrophils are elevated in
COPD patients [132]. In vivo studies demonstrate decreased neutrophil apoptosis in OSA
patients and increased expression of adhesion molecules [133]. The adhesion of these cells to
endothelium is a key step in atherosclerosis and endothelial dysfunction.
In summary, the ‘’overlapping pathways’’ activating inflammation and oxidative stress in
overlap patients are poorly understood and further investigations at the molecular level are
required for a better understanding of these processes and their abrogation in clinical practice.
6.5.2. Cardiovacular comorbidity and oxidative stress in overlap vs OSA
6.5.2.1. Hypertension, target organ damage, and oxidative stress
Large scale epidemiological studies have demonstrated an independent relationship between
OSAS and cardiovascular disorders, particularly systemic hypertension [134,135], but also
coronary heart disease, congestive heart failure, and stroke [136,137]. The presence of moderate
to severe OSA as indicated by an AHI>15 events/h leads to a relative risk of 2,89 of developing
hypertension over 8 years, after adjustment for potential confounders. The prevalence of
hypertension is over 50% in OSAS patients. Hypertension in OSAS patients is particularly
nocturnal and potentially driven by sleep disordered breathing.
We performed BP monitoring in 20 (77%) of the overlap and 12 (52%) of the OSA patients in
our study. We compared the haemodynamic characteristics and clinical factors associated with
them. BP was measured according to European Society of Hypertension (ESH)/European
Society of Cardiology (ESC) guidelines. The following parameters were measured: systolic BP
(SBP) and diastolic BP (DBP). Hypertension was defined as a SBP >140 mmHg and/or a DBP
> 90 mmHg. Ambulatory BP monitoring (ABPM) was performed with a BOSO device (Bosch
&Sons, Gruningen, Germany). The measurements were made every 20 min over 24 h. Daytime
(07:00–22:00 h) hypertension was defined as daytime SBP > 135 mmHg and/or daytime DBP
>85 mmHg, and nocturnal (22.00–07:00 h) hypertension as SBP >120 mmHg and/or nocturnal
DBP > 70 mmHg. Dipper pattern was defined by a nocturnal fall of BP >10%. Twenty of the
overlap patients and 12 of those with OSA agreed to undergo the procedure.
In the overlap group, 75% (15) were non-dippers and 25% dippers. Nocturnal hypertension
was found in 12 (60%) patients. The daytime systolic and diastolic BP’s were 121.93±17.09
mmHg and 70.93±8.12 mmHg. The nocturnal SBP and DBP were 112.76±5.38 mmHg and
68.16±3.34 mmHg. In OSA patients, 58% (7) were non-dippers and 42% dippers. Nocturnal
hypertension was found in 7 (58%) patients. The daytime systolic and diastolic BP were
138.3±13.64 mmHg and 84.38±8.20 mmHg. The nocturmal SBP and DBP were 133.90±18.89
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mmHg and 76.80±11.65 mmHg. We could not find an association between any of the studied
parameters; anthropometric (age, BMI, waist and neck circumference), sleep (AHI, average
desaturation, time of sleep at SaO2<90%), gas exchange (PaO2 and PaCO2) and ventilatory
(FEV1, FVC) and daytime/nighttime systolic/diastolic BP in any of the groups. Though the level
of urinary isoprostanes was higher in the overlap group, they did not correlate with the
haemodynamic characteristics either.
An echocardiogram and carotid ultrasonography were also performed to compare the degree
of target organ damage in overlap and OSA patients and to explore the role of urinary 8-
isoprostanes. The echocardiogram was performed using a PhilipsiE33 machine. The exami‐
nation was performed in M-mode with two-dimensional (2D) guidance in the long axis of the
left parasternal view. LV internal end-diastolic and end-systolic diameters, as well as inter‐
ventricular septum and posterior wall thicknesses were measured over five consecutive cycles.
Systolic function was assessed by the LVEF according to the Teicholz formula. LV mass (LVM)
was measured according to the Penn convention using the Devereux formula and was
normalised for body surface area (BSA) to derive the LVM index (LVMI). LVH was defined as
an LVMI of >111 g/m2 in males and of >106 g/m2 in females. The relative wall thickness (RWT)
was calculated as the ratio (2xPWT)/LVIDd. All echocardiograms were performed by the same
experienced echocardiographer.
In OSA and overlap patients, LVMI and RWT were, respectively: LVMI 123.97 vs 142.1 g/m2,
p=0.013; RWT – 0.44 vs 0.46, p=0.045. The LVMI and RWT were significantly higher in the
overlap patients, even after adjustment for AHI, BMI, SBP and DBP. Microalbumiuria was
measured and standardized to creatinine excretion and given as ratio – mg/mkmol/l Creat.
The micralbuminuria level in OSA was 5.69mg/mkmol/creat. In the overlap patients, it was
significantly higher, 26.17mg/mkmol/creat, irrespective of confounding variables (p=0.041). 8-
Urinary isoprostane levels correlated with neither LVMI nor the degree of microalbuminuria.
6.5.2.3. Atherosclerosis and oxidative stress
Patients with severe OSA are more likely to die of cardiovascular causes than those without
OSAS [45]. While the absolute risk attributable to SDB is relatively small at an individual level,
the high OSA prevalence makes it an important contributor to cardiovascular morbidity and
mortality at populational levels. Several reports have stated that OSA may also contribute to
coronary heart disease [138]. Studies utilizing carotid ultrasonography have shown severe
OSA to be associated with increased intima-media thickness (IMT) which is a marker of
atherosclerosis [139]
In our investigation, we assessed carotid artery IMT by B-mode ultrasound scanning with an
11-MHz linear phase array transducer. Bilateral IMT measurements were obtained in the distal
10 mm of the common carotid artery. The IMT was defined as the distance between the leading
edge of the luminal echo to that of the media/adventitia echo and analyzed with a computer‐
ized edge-detection system. Three end-diastolic frames were selected, digitized, and analyzed
for the mean IMT, and the average reading from these 3 frames was calculated for both right
and left carotid arteries. The sole carotid scan operator was blinded to the clinical status of the
studied subjects and was not involved in the clinical assessment. IMT was almost similar in
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both groups. In the overlap patients the average IMT was 0.90 while in the overlap group it
was 0.89.
In our study, nocturnal blood pressure abnormalities were similar in overlap and OSA only
patients. Those with overlap syndrome had greater target organ damage (cardiac-left ventric‐
ular hypertrophy and renal – microalbuminuria) in comparison with age and AHI matched
OSA patients, even after adjustment for confounders (BMI, average desaturation, time of sleep
at SaO2<90%, duration of hypertension, current therapy). Giving this statement we should
point out that it refers to OSA of moderate severity and overlap patients with moderate SDB
and airflow obstruction. Both patient groups had extreme obesity. A disadvantage of the study
is that the historical information for the management of hypertension was self reported and
thus subjective.
6.5.2.4. Metabolic disorders in overlap and OSA patients
Many studies confirm the greater prevalence of metabolic syndrome in OSA patients. Both
glucose and lipid metabolism abnormalities have been reported [140]. The role of intermittent
hypoxia, sympathetic activation and sleep fragmentation has been reviewed [141]. Compara‐
tive data regarding the metabolic disturbances in overlap syndrome, COPD, and OSA are still
lacking. The effect of both disorders in overlap syndrome, their additive and/or synergistic
interaction, and physiological pathways on metabolism is not well understood.
In our investigation, we measured parameters of glucose metabolism in the overlap and OSA
patients. A correlation analysis with oxidative stress markers (8-isoprostanes) was performed.
Using enzymatic colorimetry plasma levels of total cholesterol, triglycerides, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol (using the Friedwald formula),
glucose, immuno-reactive insulin, and HOMA-index were measured. An oral glucose
tolerance test (OGTT) was performed to detect glucose metabolism abnormalities.
Diabetes was found in 30% of the overlap patients, 50% were healthy, and 20% had an impaired
glucose tolerance. In OSA patients, 33% were diabetic, 44% were healthy, and an impaired
glucose tolerance was found in 23%. Although the average parameters tended to be higher in
overlap vs OSA patients resp-IRI-21.04±15.46 mU/l vs 18.37±9.95 mU/l; average fasting blood
glucose-6.19±2.86 mmol/l vs 5.73±2.03 mmol/l, HOMA-I 5.52±4.03 vs 4.84±2.64; there were no
statistically significant differences. Only the glycosylated hemoglobin was significantly
higher-6.51±1.24 vs 5.91±1.07, p<0.05 and remained significantly different after adjusting for
confounders (age, BMI, AHI). FEV1, PaO2, and PaCO2 did not correlate any of the glucometa‐
bolic parameters. A positive correlation between HbA1c and urinary 8-isoprostanes was
established, p=0.023. The lipid profiles in both groups were similar. Dyslipidemia was present
in 50% of overlap and 47% of OSA patients. In OSA and overlap patients, they were respec‐
tively-HDL 1.24±0.4 mmol/l vs 1.20±0.23 mmol/l; LDL 3.13±0.81 mmol/l vs 3.14±1.00 mmol/l;
Tot chol – 5.30±0.95 vs 5.27± 1.6 mmol/l; Triglycerides – 2.82±1.24 vs 2.06±1.03 mmol/l. FEV1,
PaO2, PaCO2 and urinary isoprostanes did not correlate with any of the lipid profile parame‐
ters.
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In conclusion, our study showed that the prevalence of glucometabolic abnormalities in the
overlap and OSA patients was similar. The glucometabolic parameters for patients with
overlap syndrome, however, were worse in comparison with OSA only. HbA1C levels were
associated with the level of oxidative stress-urinary 8-isoprostanes. The prevalence of dysli‐
pidemia and lipid profile parameters in both groups were almost identical and were not
associated with the marker of oxidative stress. Our OSA subjects had moderately severe OSA
and overlap syndrome patients had moderate SDB and airflow obstruction. Both patient
groups had extreme obesity.
6.6. Sleep quality in overlap
In OSAS patients, one of the most common symptoms is excessive daytime somnolence, which
results from disrupted sleep or/and nighttime oxygen desaturation [142,143]. Mild to moderate
COPD patients usually do not have significant daytime sleepiness. Fatigue and tiredness are
more common [59,144].
Sanders et al [55] studied 1132 patients with mild COPD and observed that COPD only patients
had minimally perturbed sleep in the absence of OSA. Sleep architecture did not correlate with
the level of airflow obstruction. There were small but not statistically significant differences
between patients with or without COPD with regards to Epworth Sleepiness Scale (ESS), total
sleep time, arousal index, lower total sleep time, and sleep efficiency. Only small differences
were found between patients with OSA alone or those with both disorders, suggesting that
sleep quality in overlap patients is mainly influenced by the presence of OSA. This is confirmed
by Redline et al [56]. They demonstrated that sleep structure characteristics did not change in
subjects with a history of lung disease but sleep stage distributions varied according to AHI
level.
Analysing the data from our investigation, we found that the ESS was the same in patients
with overlap syndrome and OSA only. The average ESS score in the overlap group was 15±4.3
while in the OSA only patients, it was 14±5.8. The sleep study characteristics in OSA and
overlap were respectively – stage 1-30.1±9.59/27.04±7.7 min; stage 2-27.5±11.3/33.7±716.5 min;
stage 3+4-28.35±17.12/31.87±16.43 min; AI – 31.6 vs 36.4 apneas/h; sleep efficiency was 69% in
OSA and 64% in overlap patients. Though the duration of sleep with SaO2<90% was much
longer for the overlap patients, it correlated neither to the level of 8-isoprostanes (oxidative
stress) nor to the ESS. The degree of airway obstruction (measured by FEV1) did not correlate
with sleep stage distribution, AHI, AI, or ESS.
6.7. Clinical presentation
The most common symptoms of OSA patients аre snoring, excessive daytime sleepiness, and
deterioration of quality of life [145,146]. COPD patients, on the other hand, may present with
cough, sputum production, and/or dyspnea [64]. Nevertheless, overlap patients possess a
unique characteristic, which sets them apart from either COPD or OSA patients. A number of
studies compare the clinical presentation of overlap patients to those of OSAS-only patients.
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Chaouat et al [87] stated that compared to the OSA only group, the overlap patients tended to
be older, had hypoxemia and hypercapnia more frequently and had higher mean pulmonary
artery pressures but similar body mass index (BMI). O’Brien and Whitman [147] found that
overlap patients were older and less obese. Resta et al [148] showed that overlap patients had
higher PaCO2, but similar apnea–hypopnea indices (AHI).
Kessler noted that in OSAS patients exhibiting permanent pulmonary hypertension, bronchial
obstruction is generally not severe and the level of hypoxemia and hypercapnia is modest.
Therefore, chronic airway obstruction in these patients may be asymptomatic. These findings
suggest that the performance of pulmonary function tests in all patients diagnosed with OSAS
by a polysomnogram might be beneficial to detect occult airflow obstruction [149].
In our investigation, we observed 26 patients with overlap syndrome and compared them to
23 age and AHI matched patients with OSA only. In the overlap group, the mean FEV1 was –
53.5±10.87%; FVC-55.5±24.5% ; FEV1/FVC-64.46±9.19% The average daytime PaO2 was
61.67±5.78 mmHg. Five (19%) patients had daytime hypercapnia and their average daytime
PaCO2 was 52.14±11.39 mmHg. The patients had the following anthropometric charactersis‐
tics: mean age-46.83±8.62 y; BMI-41.89±4.57 kg/m2; waist circumference – 133.11±10.94 cm;
neck circumference – 48.54±3.92 cm. One (3%) was a non-smoker. In our overlap group,
pulmonary hypertension was detected in 84.6% with an average systolic pulmonary pres‐
sure-38.87 mmHg.
A group of 23 age and AHI matched OSA patients were selected from the registry of sleep lab
patients. The average daytime PaO2 was 75.59±8.43 mmHg. None of the patients had hyper‐
capnia and the average daytime PaCO2 was 36.25±6.11 mmHg. The patients had the following
anthropometric charactersistics: mean age-49.95±10.54 y; BMI-37.47±7.98 kg/m2; waist
circumference – 126.43±11.28 cm; neck circumference – 45.46±4.49 cm; Four (17%) were non-
smokers. The ventilatory parameters in the OSA only group were: FVC-77.25± 19.6%;
FEV1-62.25±20.22%; FEV1/FVC-86.9±8.85%. In the group of patients with OSA only, pulmonary
hypertension was found in 47.8% with average systolic pulmonary pressure – 34.16 mmHg.
The Epworth sleepiness score (ESS) was similar in both groups-overlap-15±4.3 vs OSA only
14±5.8.
According to our results the overlap patients were younger, had increased BMI, waist and
neck circumferences in comparison to the OSA only patients. The AHI, AI, the duration of
sleep with SaO2<90% as well as the daytime gas exchange abnormalities were more severe in
the overlap group. The sleep complaints however were almost identical. The degree of PH was
similar in both patient groups. The prevalence of pulmonary hypertension in the overlap
syndrome was almost two fold greater than in the OSA only group. It was, however, dispro‐
portionate to what should be expected from the gas exchange parameters. As our results are
not in agreement to those mentioned above, we should point out that our investigation was
performed in patients with extreme obesity, which more or less reflects the respiratory drive,
respiratory mechanics and pulmonary haemodynamics. They should be compared to patients
with a moderate degree of sleep disordered breathing and excessive sleepiness and/or
disturbed sleep.
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6.8. Current guidelines and recommendations in the diagnostic approach to overlap
syndrome in OSA patients
Nocturnal polysomnography is recommended in COPD patients whose symptoms suggest
coexistent OSA. This encompasses COPD patients with daytime hypercapnia and moderately
reduced FEV1; COPD snorers, or those who develop headache after nocturnal oxygen therapy
[25,64]. Apneas while asleep and daytime sleepiness are highly suggestive of OSA [65].
However, the presence of concomitant OSA is often difficult to predict. A large number of
patients with OSA do not have daytime hypercapnia or headache and some of them are not
obese. Daytime sleepiness is often absent. The significant cardiovascular morbidity and
mortality related to untreated OSA and its reversibility with CPAP treatment strongly
demands a more aggressive approach in diagnosing coexistent OSA among patients with
COPD [150,151].
The recognition and diagnosis of COPD may be challenging in patients with OSA. Smoking
history should always be obtained. COPD among OSA patients should be suspected if daytime
hypercapnia, pulmonary hypertension, and nocturnal tachyarrhythmias are present.
[42,87,106,148]. Chaouat et al [87] performed a study in 265 patients. They found that the
prevalence of daytime hypercapnia was 27% in the 30 patients with associated COPD and 8%
in the 235 patients without COPD. Daytime hypercapnia was observed in 11% of 1141 OSA
patients who were free of COPD and was related to the severity of obesity [152]. Pulmonary
hypertension is observed in 75% of patients with coexistent OSA and COPD [42] and in only
12%–20% of unselected OSA patients [102]. Patients with coexistent OSA and COPD are 2.53
times more likely to experience tachyarrhythmias during sleep than patients with OSA alone
[106].
In summary, patients with OSA who do not carry a diagnosis of COPD but have daytime
hypercapnia, pulmonary hypertension, and/or nocturnal tachyarrhythmias should undergo
pulmonary function testing (table 2). On the other hand, COPD patients with witnessed
apneas, daytime sleepiness, obese snorers, those who have daytime hypercapnia and/or
pulmonary hypertension, and/or daytime hypoxaemia disproportionate to their FEV1 should
undergo a polysomnography study.
OSA
Daytime hypercapnia disproportionate to obesity
Pulmonary hypertension
Tachyarrhythmias
Table 2. Indications for performing a pulmonary function testing in OSA
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7. Treatment of nod in copd patients
7.1. Medications – bronchodilators, corticosteroids, hypnotics
7.1.1. Effect on sleep quality
Ipratropium improves sleep quality [153] in patients with moderate to severe COPD, while
tiotropium has no effect [154], at least not in patients with severe COPD. Data regarding
theophylline have been variable, with some studies showing sleep disturbances [155], and
others showing no changes [156-58]. 28% of COPD patients use hypnotics because of insomnia
and other sleep disorders. Benzodiazepines are not recommended as they worsen nocturnal
hypoxemia [159]. Non-benzodiazepine compounds like Zolpidem are safer [160].
7.1.2. Effect on NOD
Bronchodilators have variable effects on sleep quality but they significantly improve NOD.
Theophylline [155,157], ipratropium [153], and tiotropium inhalers [154] have shown im‐
provements in NOD. Martin et al studied the effect of ipratropium, taken 4 times a day in 36
patients with moderate to severe COPD (FEV1 <65%) [153]. After a month of treatment,
nocturnal oxygen saturation decreased, subjective sleep complaints improved, and total REM
time increased. Tiotropium also improved nocturnal oxygen saturation but sleep quality
remained unchanged [154]. Long-acting β2 agonists have similar benefits [161]. Oral steroids
in stable COPD improve nocturnal oxygen desaturation and increase total sleep time [162].
Despite the lack of data, we might suggest that inhaled corticosteroids may have a similar
effect.
7.2. Oxygen
7.2.1. Effect on sleep quality
A limited number of studies have examined the effect of oxygen therapy on sleep. A decrease
in sleep latency, increase in total sleep duration, and REM were noted by Calverley et al [6].
Fleetham et al [57] noted no improvements in total sleep time (TST), sleep stages or frequency
of arousals with the addition of oxygen.
7.2.2. Effect on NOD
In COPD patients with severe daytime hypoxemia (49-52 mm Hg), and nocturnal desatura‐
tions, it has been clearly established in both the British Medical Research Council (MRC) Long-
Term Domiciliary Oxygen Therapy Trial [164] and the Nocturnal Oxygen Therapy Trial
(NOTT) [165] that continuous oxygen therapy improves survival. This improvement was seen
in comparison to supplemental oxygen administered only at night. COPD patients with
hypoxemia only during sleep may also have increased mortality risk [166]. The correction of
nocturnal hypoxaemia alone in patients with daytime normoxia does not significantly improve
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pulmonary haemodynamics or mortality [38], but it may improve sleep quality and is
frequently prescribed [6].
Oxygen therapy for COPD patients with moderate daytime hypoxaemia and nocturnal
desaturations remains very controversial. After a 3 year follow-up, no difference in survival
among COPD patients with moderate hypoxaemia (PaO2 56 and 69 mm Hg) was noted
between the supplemental oxygen therapy group (average use of 14 h/d) and the control when
[167]. Fletcher et al [168] found no survival benefit in COPD patients with NOD and an awake
PaO2 > 60 mm Hg, when randomized to 3 L/minute of oxygen or sham control for 36 months.
Pulmonary hemodynamics, however, improved in the oxygen therapy group. In a 5-year
follow up study, Chaouat et al [39] found no survival advantage in COPD patients with
PaO2 56-69 mm Hg who were randomized to oxygen therapy versus a control group. They
found no difference in the progression of COPD to respiratory failure or the development of
pulmonary hypertension.
The effect of long-term oxygen therapy on mortality in COPD patients with isolated nocturnal
oxyhemoglobin desaturation remains unclear. Pooling together COPD patients with and
without nocturnal oxyhemoglobin desaturation may mask the benefit of long-term oxygen
therapy on survival in COPD patients with nocturnal oxyhemoglobin desaturation only.
In summary, survival benefit of long term oxygen therapy is attained in COPD patients with
severe daytime hypoxaemia. Based on current data, oxygen therapy is unproven in COPD
patients with moderate daytime hypoxemia and NOD, or in COPD patients who experience
only NOD. Improvement of pulmonary haemodynamics and sleep quality with oxygen is also
unproven.
7.3. Non-invasive positive pressure ventilation (NIPPV)
The role of NIPPV has been clearly established in COPD patients with an acute exacerbation.
Data about its role in stable COPD patients is missing. Studies present mixed results and vary
depending on the design. A recent systematic review of NIPPV in severe stable COPD patients
was conducted by Kolodziej et al. [169]. They reviewed 9 randomized controlled trials (RCTs)
and nine non-RCTs. No improvement in gas exchange with NIPPV among the RCTs was
found. In the non-RCTs a reduction in lung hyperinflation and diaphragmatic work of
breathing was noted. Improvement in gas exchange was also established [169]. Although
NIPPV may have favorable effects, its therapeutic role has not been firmly stated for stable
COPD patients. Despite this, the application of NIPPV in medical centres has been increasing.
Recommendations from the American College of Chest Physicians (ACCP) were published to
help clinicians in guiding therapy with NIPPV in stable COPD patients. According to ACCP
guidelines, NIPPV may be considered in stable COPD when symptoms (fatigue, morning
headache, daytime hypersomnolence) and one of the following is present: 1. PaCO2 > 55 mm
Hg; (OR) 2. PaCO2 – 50-54 mmHg and NOD (overnight oximetry with SaO2 < 88% for 5 min
while on oxygen therapy > 2 L/minute; (OR) 3. PaCO2 50-54 mm Hg and hospitalization related
to recurrent episodes (>two in a 12-month period) of hypercapnic respiratory failure [170].
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Two recent results deserve attention. McEvoy et al [171] performed a randomized controlled
trial of NIV in patients with stable hypercapnic COPD which showed a significant improve‐
ment in adjusted mortality. Little or no change in pulmonary function or daytime blood gases
was detected. The improvement in mortality was associated with a worse quality of life with
NIV. A second study by Windisch et al [172] also reported mortality improvements with NIV,
although compared to historical controls. They used “high-intensity NIV” with very high
driving pressures (average inspiratory pressure 28cm H2O, average expiratory pressure 5 cm
H2O) and a high respiratory rate (21 breaths/min). Under these settings, there were also
improvements in spirometry and blood gases.
8. Treatment of nod in copd patients with osa – the overlap syndrome
The aim of the treatment of patients with overlap is to avoid desaturations and sleep-disor‐
dered breathing. Treatment should be individualized according to the degree of OSA and/or
COPD severity and in consideration of the co-existing illnesses – obesity, heart failure,
pulmonary hypertension. All patients should however be advised about the potential benefits
of therapy and the risks of going without it. Although CPAP therapy is a well-established
treatment for OSA, it is not suitable for all overlap patients [173,174]. Auto-titrating CPAP is
not recommended in COPD and overlap patients. Treatment options may also include oral
appliances, additional supplement of oxygen or non-invasive positive pressure ventilation
(NPPV).
8.1. General recommendations and medications
All patients should be advised of the importance of avoiding factors that increase the severity
of upper-airway obstruction such as use of alcohol, smoking, hypnotic agents, and increased
weight [175]. Data suggest that treatment of COPD in overlap syndrome will ameliorate
nocturnal oxygen desaturation, and may decrease the need for supplemental oxygen in
addition to CPAP [83]. Whether treatment of COPD in the overlap syndrome also improves
OSA is not known.
8.2. Oxygen
The benefit of supplemental oxygen therapy alone in OSA is lacking [176]. After two-weeks
of oxygen administration, nocturnal oxygen desaturation is improved, but sleep architecture,
arousals, and subjective sleepiness are not. Alford et al applied 4 L/min supplemental oxygen
to 20 overlap patients; NOD improved, but the duration of obstructive events increased which
resulted in an increase of end-apneic PCO2 from 52.8 mm Hg to 62.3 mm Hg. Thus, oxygen
alone should not be used for the treatment of the overlap syndrome.
8.3. Continuous positive airway pressure
CPAP remains the standard treatment for OSA and is the accepted therapy for overlap
syndrome. Its effect however depends on the severity of OSA/COPD and on the presence of
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comorbidities. In some patients CPAP alone may not fully correct hypoxaemia and supple‐
mental oxygen may be required [177]. In hypercapnic COPD patients however it is not
recommended.
COPD patients with mild sleep-disordered breathing and severe nocturnal hypoxaemia may
not tolerate CPAP. They may be better managed with oxygen. As most of the oxygen trials
were performed at the time when polysomnography was not widely used, further evaluation
of its benefits in COPD patients with mild sleep apnea should be performed.
CPAP is better tolerated in COPD patients with moderate/severe OSA. Data about its effects
on daytime lung function is controversial. Some authors suggest that upper-airway irritation
increases lower-airway resistance and correction of repetitive airway collapse might improve
pulmonary function [177]. Others postulate that CPAP off-loads the respiratory muscles,
decreases hypoventilation, oxygen consumption, and carbon dioxide production. During sleep
these muscles may be alleviated by CPAP, since it prevents the increase of upper-airway
resistance that occurs in sleep [178]. In severe COPD, CPAP may offset intrinsic PEEP in severe
COPD. In 8 COPD-only patients, Mezzanotte et al, [179] applied CPAP for 1–3 weeks. They
assessed inspiratory force and endurance and found significant improvements in maximum
inspiratory force and 12-min walk test. Improvements have also been observed in daytime
oxygenation and hypercapnia, [180,181] and in the number of COPD-related hospital admis‐
sions following the start of CPAP treatment for OSA [182].
Conflicting spirometry results have been seen when CPAP is used in the overlap syndrome.
A few non-randomized studies have shown improvements in FEV1, PaO2, PaCO2, after CPAP
initiation [84,103,180]. The largest study (55 patients), by de Miguel et al [84] observed
significant improvements in FEV1, FVC, and PaCO2 after 6 months of CPAP therapy. Both
spirometry and gas exchange parameters remained improved for 18 months after CPAP
cessation.
The addition of long-term CPAP therapy to standard treatment of COPD patients may also
improve gas exchange while reducing hospitalization rates in patients with COPD and OSA
[84,180]. The improvement in gas exchange with CPAP has important implications when
assessing the necessity of long term oxygen therapy in patients with coexistent COPD and
OSA. Among 55 middle-aged men with daytime hypoxaemia and coexistent COPD and OSA,
only 22% continued to have daytime PaO2<60 mmHg after 6 months of CPAP therapy [84].
Furthermore, CPAP therapy reduces elevated pulmonary and systemic arterial pressures in
OSA [103,183] which emphasizes the importance of timely diagnosis and treatment of
coexistent COPD and OSA. A substantial weight loss in that trial (mean weight loss approxi‐
mately 15 pounds) could also explain part of the improvement. A negative study by O’Brien
found that the overlap patients who were most adherent to CPAP had the greatest decline in
lung function [151]. This could reflect bias, since those patients with the most progressive
disease and symptoms may have used CPAP the most (or were urged to do so by their
physicians). The small number of patients (35), the fact that only one third of them were
included in the final analysis, the lack of precise timing of baseline and follow-up pulmonary
function testing, makes these data difficult to interpret.
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Long-term follow-up and outcomes of CPAP therapy in the overlap syndrome have only
recently been reported. In an observational study, Machado et al [184] evaluated 95 patients
with moderate-to-severe OSA and hypoxaemic COPD. Patients were hypoxaemic and
hypercapnic at rest. They received long term oxygen therapy (LTOT). 61 patients received
CPAP, the remainder were not adherent to ventilatory treatment. The five-year survival was
71% in the CPAP treated and 26% in the non-treated group. The adjustment for confounding
factors showed that patients treated with CPAP had a significantly lower risk of death.
Marin et al [150] studied 441 patients with overlap syndrome (228 patients were treated with
CPAP and 213 not treated) and 210 patients with COPD only for almost ten years. The co-
existence of OSA/COPD was associated with an increased mortality (particularly cardiovas‐
cular) compared to COPD alone. Secondly, effective CPAP treatment of OSA reduces mortality
in overlap patients. Finally, patients with overlap not treated with CPAP were more likely to
suffer severe COPD exacerbations and hospitalizations in comparison to the COPD only
group. In both studies, however, CPAP was not provided in a randomized, blinded manner.
8.4. Non-invasive ventilation
While CPAP therapy is effective in most OSA patients with or without coexistent COPD,
bilevel positive airway pressure (PAP) may be useful when overlap patients experience
difficulty exhaling against pressure or when, despite the adequate airflow during CPAP
titration, intermittent nocturnal hypoxemia persists [185]. This is usually observed in severe
COPD patients who hypoventilate during the night. In such cases bilevel devices should be
considered. Bilevel PAP delivers a lower expiratory PAP and higher inspiratory PAP thereby
augmenting ventilation [186,187]. In overlap patients who experience persistent intermittent
nocturnal hypoxemia despite the adequate airflow during CPAP or BiPAP the positive airway
pressure can be increased to ameliorate possible residual upper airway resistance. If increased
PAP is ineffective or poorly tolerated, supplemental oxygen can be added [188].
The current guidelines suggest initial follow-up within 1 month after the start of PAP treat‐
ment. Subsequent visits should be annually or as needed The objective monitoring of PAP
compliance is strongly recommended [185]. The close follow-up of patients includes patient
education, adjustment of facial interfaces, and treatment of nasal conditions [185].
The effects of bilevel PAP on overlap syndrome have not been evaluated.
In our investigation, we followed 21 overlap patients who were adherent to BiPAP therapy
after a period of one month. A slight improvement in ventilatory parameters was detected:
FEV1 53.5±10.87% vs 62.1± 9.18; FVC-55.5±24.5% vs 64.8±17.19% (Figure 3). A minor correction
of blood exchange abnormalities was also observed (Figure 3). The average daytime PaO2
increased from 61.67±5.78 mmHg to 69.32±7.18 mmHg (Figure 3). Hypercapnia was compen‐
sated in 43% of the patients and decreased from 52.14±11.39 mmHg to 48.32±8.17 mmHg.
Though not of statistical significance, oxidative stress, as measured by urinary 8-isoprostanes,
was also lower after one month of BiPAP therapy – 0.251±0.10 vs 0.214±0.12. The subjective
sleepiness (ESS) improved from 15±4.3 to 12±3.8; this is related to an improvement of sleep
disordered breathing. A reduction of IRI was also detected 21.04±15.46 vs 19.13±9.21 mU/l. Our
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data suggests that BiPAP therapy improves gas exchange and ventilatory parameters in
overlap partients. It reduces the oxidative stress level and alleviates sleep complaints. Com‐
parative data with CPAP is however missing. Whether long-term NIV would improve
outcomes in the overlap syndrome, compared to CPAP is also unknown.
Before BiPAP treatment After BiPAP ventilation
FVC (l) 1.52 1.61
FEV1 (l) 1.12 1.18
pH 7.41 7.46
PaO2 (mmHg) 66.8 69.9
PaCO2 (mmHg) 39.5 35.9
Figure 3. Representative spirometric and gas exchange parameters before and after treatment with BiPAP for one
month from a single patient.
9. Conclusions
Sleep disturbances and NOD are common in COPD patients. Those patients with severe
disease have both subjective and objective complaints of poor sleep quality and are easily
suspected to experience NOD. The challenge to clinicians is to detect NOD among COPD
subjects with mild daytime hypoxaemia where the clinical parameters predisposing patients
to NOD are not as well recognized.
OSA is an independent, contributing mechanism to NOD in almost half of COPD patients who
experience nighttime desaturations. The overlap syndrome though highly prevalent is
frequently unrecognized in clinical practice. Daytime sleepiness and naps are not universal
for OSA patients and the failure of clinicians to consider SDB in COPD is the reason for its poor
detection. Overlap syndrome is associated with greater hypoxaemia and hypercapnia than
COPD and OSA alone, which may have cardiovascular implications. Its early recognition and
treatment with positive pressure ventilation may reduce morbidity and mortality and is
strongly recommended.
According to our investigation, overlap patients have a higher prevalence of metabolic and
cardiovascular disorders in comparison to OSA alone. Even after adjustment for confounding
variables, the level of oxidative stress (measured by urinary 8-isoprostanes) is significantly
higher in the overlap syndrome compared to OSA alone. One month treatment with BiPAP
improved the ventilatory and gas exchange parameters and decreased the oxidative stress level
in overlap patients. Despite the lack of weight reduction, a significant improvement in
glucometabolic parameters was established.




The new definitions of OSA proposed by the American Association of Sleep Medicine (AASM),
based on epidemiological data sets are a major change of perspective that may facilitate the
diagnostic approach to overlap [92]. The data regarding the prevalence of OSA in the general
population and in COPD must be re-analysed. This is especially important to reestablish
clinical phenotypes of both diseases in order to acquaint clinicians with the signs and symp‐
toms that are highly suggestive of OSA in mild/moderate COPD and those suggestive of COPD
in OSA patients.
‘Molecular” and “physiological” studies are needed to evaluate the role of oxidative stress and
inflammation in overlap syndrome as well as its possible additive and/or synergistic effects
on cardiovascular morbidity. Biomarkers, indicative of increased cardiovascular risk are also
demanded.
The introduction of more standardized therapeutic approaches is mandatory. The effects of
oxygen therapy in COPD patients with only nighttime hypoxaemia and/or mild daytime
hypoxaemia are unknown, especially those regarding gas exchange and pulmonary haemo‐
dynamics outcomes.
Overlap patients have severe daytime hypoxaemia than is expected based on lung mechanics.
The effect of CPAP on dayime hypoxaemia in overlap syndrome has not, however, been
investigated. It is obvious from the study of Machado et al, that some indications for LTOT
should be reconsidered in a group of overlap patients; follow-up visits and reevaluation of
ventilatory therapy should also be performed in detail. CPAP is the first choice in a phenotype
of overlap patients where “OSA is prevalent”. The optimal therapy for patients with mild OSA
and moderate/severe COPD or for those with mild OSA and COPD remains a challenge.
It is obvious that CPAP is not as safe in COPD as is generally supposed. Holanda et al stated
that in COPD, CPAP increased lung volume and worsened the baseline level of alveolar
hyperinflation [189]. The AASM has proposed non-invasive ventilation for treatment of
patients with overlap syndrome, especially for those intolerant of CPAP, or those with severe
nocturnal hypoxia and/or hypoventilation. Pressure support ventilation stabilizes the upper
airways in patients with OSA or overlap, as it changes the level of effective pressure between
inspiration and expiration. It is also the most common mode of ventilation for the management
of COPD related nocturnal hypoventilation.
Comparative follow-up mortality studies in overlap patients treated with either CPAP or
BiPAP modality are required to determine the optimal therapeutic management.
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